What COSCIENS' $15 Million 'Acquisition' Really Is: One-Year 15% Debt That Could Nearly Double the Share Count

On September 10, COSCIENS Biopharma — a Toronto life-sciences micro-cap worth a few million dollars — announced it had acquired a Montreal pharmaceutical-technology business called Nualtis. The headline number is US$15 million. The number the headline leaves out is how COSCIENS is paying for that invoice, and that is the part that actually tells a shareholder what they are buying.

The price and the pause

The deal is a cash purchase on paper. US$9 million was paid at closing, and another US$6 million comes due within six months. A seller can also collect up to four earn-out payments equal to 10% of Nualtis's adjusted EBITDA in the years 2027 through 2030 — a reward tied to results those years never delivered yet.

The first thing to notice is the size of the check relative to the hand signing it. COSCIENS closed the first quarter of 2026 with about US$1.9 million in quarterly revenue and roughly US$5.0 million in cash. Its entire market value sits in the single-digit millions of U.S. dollars. A US$15 million purchase is roughly two to three times what the whole company is worth. This is not a company buying a business bigger than itself. It is a company buying a business roughly the size of itself — with someone else, or tomorrow's shareholders, expected to cover the tab.

The debt that does the heavy lifting

To fund the closing, COSCIENS placed a non-brokered private placement of unsecured convertible debentures. The first tranche raised about US$6 million, and the company says it contemplates up to US$20 million in aggregate principal across one or more additional tranches, with a second expected within a week. Read the terms, because they carry the economics.

The notes pay 15% annual interest, monthly, and mature on September 10, 2027 — one year out. Conversion is at US$7.00 a share, with a "ratchet" that lowers that conversion price if the company later raises equity below US$7.00 before maturity. Full conversion of the first US$6 million tranche would mint roughly 850,000 new shares — about 85% of the ~997,000 shares COSCIENS had outstanding on the day of the announcement.

That is the number the press release owns outright, and it deserves a hard look. Fifteen percent interest on a one-year maturity is expensive, short-dated financing for a company whose whole stock is worth only a few million dollars. And the conversion price of US$7.00 sits just above a stock that trades around C$7.50 — roughly US$5.50. So the notes convert only if the shares rally about a quarter from here, or if the ratchet steps the conversion price down. If the stock does not cooperate, all US$6 million plus a year of 15% interest comes due in cash within twelve months. The two ways out of that corner — convert and roughly double the share count, or refinance on similar terms — are both paid by the existing owners.

There is more texture in the placement. Directors and officers subscribed for about US$1.3 million of the notes, and a finder was owed US$181,250. Insider participation cuts both ways: it aligns their money with the trade, and it also means the people setting these terms were on the other side of the table at them. The conversion rights and the ratchet require shareholder approval under TSX rules, and COSCIENS has agreed to call a meeting within six months — so the dilution math above is the headline, and the vote that could confirm or concentrate it is still to come.

What was actually bought, and how much cash it makes

Here is where the story loops back on itself. Nualtis is the reorganized remains of IntelGenx, a Montreal oral-thin-film company founded in 2003 that filed for creditor protection in Canada in May 2024 and was carried out through a court-approved sale in which an investor named AtaiBeckley exchanged its secured debt for the company. What COSCIENS bought is that survivor: the VersaFilm and VetaFilm delivery platforms, 21 foundational patents, and an FDA- and Health Canada-inspected GMP plant.

The pitch is the pipeline. RizaFilm, an approved migraine film, got a second approval for pediatric use in early 2026 and its U.S. partner plans a launch this October. A generic version of the chronic-pain film Belbuca is in development, chasing a product that booked about US$221.7 million of net U.S. revenue in fiscal 2025 with no generic on the market yet. A veterinary program is aimed at a market the company puts above US$100 million a year. COSCIENS says that if this pipeline commercializes, it could mean "tens of millions of dollars in annual revenue" within five years.

That is a forward-looking hope, and it meets its reality test quickly. In the first quarter of 2026, Nualtis itself recognized just US$0.2 million in license revenue. The asset COSCIENS just borrowed US$15 million at 15% to own is currently a business that books a rounding error of quarterly income, on top of a bankruptcy it filed less than two years ago.

Who is financing the wait

None of this is an accusation of fraud. There is no allegation here, no restatement, and the deal does not smell like a shell game so much as a leverage game. But the accounting clue — a target that briefly went bankrupt, revenue that has not arrived, and one-year debt that can nearly double the share count to close the purchase — is the part an investor should weigh before the "tens of millions" ever lands.

The buyer's own recent history adds context rather than clearing it. COSCIENS was formed in mid-2024 by merging Ceapro with Aeterna Zentaris. It has since delisted from Nasdaq (keeping the Toronto listing), suspended its U.S. reporting by filing a Form 15 in July 2026, run under an interim CEO, and deconsolidated German subsidiaries that went insolvent in the first quarter — a move that produced the company's US$10.8 million net income for the quarter, almost entirely through a one-time US$10.9 million gain from discontinued operations rather than from running a profitable business.

So here is the shareholder invoice, sized now: a 15% coupon for the next year; roughly 85% dilution baked into the conversion if the notes convert; a US$6 million deferred payment due within six months; and more debentures — up to US$20 million in total — that could widen the dilution further and could trip the ratchet on any future equity raise below US$7.00. The real question is not whether RizaFilm or a Belbuca copy someday works. It is who pays for the wait while the answer is unknown — and the terms that were just signed say it is the people who hold the shares today.